Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany Chang

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Blood|December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphomaSanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Blood Advances|March 27, 2026
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin LymphomaAyo Samuel Falade, Robert Redd, Sanjal H Desai, et al.
Anti-Cancer Drugs|August 16, 2020
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathwaysMargarite D Matossian, Hope E Burks, Steven Elliott, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Blood|December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphomaSanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Blood Advances|March 27, 2026
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin LymphomaAyo Samuel Falade, Robert Redd, Sanjal H Desai, et al.
Anti-Cancer Drugs|August 16, 2020
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathwaysMargarite D Matossian, Hope E Burks, Steven Elliott, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Pageof 8